Loading
A PET scan after two cycles of antibodies alone identifies women who can be cured without chemotherapy.
This diagnostic-therapeutic pairing uses an early FDG PET scan to decide who can omit chemotherapy in HER2-positive breast cancer treated with dual HER2 blockade. After two cycles of trastuzumab and pertuzumab alone, with or without endocrine therapy, a metabolic response on PET predicts a pathological complete response to antibody-only treatment, and that complete response in turn predicts an excellent long-term outcome. In the randomised phase 2 PHERGain trial, PET responders continued the antibodies without chemotherapy and those reaching a pathological complete response skipped it altogether; the trial met its co-primary endpoints. The phase 3 PHERGain-2 trial and similar response-adapted designs such as WSG-ADAPT are now testing the approach more broadly.
Shares Dual HER2 blockade, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares PHERGain, FDG PET, HER2-positive breast cancer.
Shares Dual HER2 blockade, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Dual HER2 blockade, Pertuzumab, Trastuzumab, HER2-positive breast cancer.